Summary
ABL’s expertise with protein-based therapies extends from the discovery of IL-2 and covers over 25 years of cGMP manufacturing support for commercial and government clients.  In addition to providing comprehensive process development and manufacturing services for microbial and mammalian processes, ABL also offers in vivo and in vitro preclinical testing to optimize the management of discovery, preclinical and clinical activities.

Services
Technology transfer
Upstream cell culture and fermentation
Downstream processing and viral inactivation
cGMP Master & Working cell banks
Analytical testing
Toxicology production
Pilot production
cGMP clinical production

Capabilities
Mammalian cell culture up to 400L
Microbial fermentation up to 40L
Baculovirus expression
Column chromatography
UF/DF
Viral inactivation studies

Experience
Monoclonal antibodies
Recombinant proteins
Cytokines
Enzymes
Glycoproteins
Conjugated antibodies

Project Management

Quality Assurance